Day 2 Program

State of the Art 1: Refining Risk and Tailoring Treatment—Liquid Biopsy for Adaptive Therapy in Breast Cancer

Day 2: December 10, 2025

1:00 PM–2:15 PM CST

Stars at Night 1-2

Session Details

This session explores the use of liquid biopsy—including circulating tumor DNA (ctDNA) and minimal residual disease (MRD) detection—to refine risk assessment and guide personalized, adaptive therapy across neoadjuvant, adjuvant, and metastatic breast cancer settings.

SA1-01

Neoadjuvant adaptive strategies: Integrating imaging and ctDNA to personalize preoperative therapy

Angela M DeMichele, University of Pennsylvania, Philadelphia, PA

SA1-02

MRD-informed adjuvant therapy: From risk stratification to personalized management

Michail Ignatiadis, Institut Jules Bordet, Brussels, Belgium

SA1-03

Guiding metastatic breast cancer treatment with pharmacodynamic and predictive liquid biopsy biomarkers

Francois-Clement Bidard, Institut Curie, Paris, France

Advocate

Tracy Edler Solak, Young Survival Coalition, Houston, TX